Table 1: Characteristics of COVID-19 patients with or without hepatitis virus infection.
Variable |
Total (n = 250) |
With hepatitis virus infection (n = 61) |
without hepatitis virus infection (n = 189) |
P value |
Male, No. (%) |
124(49.6%) |
36(59%) |
88(46.6%) |
0.106 |
Age, median(IQR) |
57.0(47.75~67.0) |
54(48~65) |
58(47~68) |
0.191 |
Temperature, median (IQR) |
36.5(36.3~36.8) |
36.5(36.4~37) |
36.5(36.3~36.8) |
0.306 |
Heart rate, median (IQR) |
82(78~96) |
80(73.5~93) |
84(80~96) |
0.029 |
Symptoms and signs, No. (%) |
|
|
|
|
Fever |
104(41.6%) |
23(37.7%) |
81(42.9%) |
0.289 |
Fatigue |
70(28.0%) |
19(31.1%) |
51(27.0%) |
0.317 |
Headache |
12(4.8%) |
3(4.9%) |
9(4.8%) |
0.595 |
Cough |
129(51.6%) |
21(34.4%) |
108(57.1%) |
0.002 |
Expectoration |
32(12.8%) |
8(13.1%) |
24(12.7%) |
0.543 |
Chest distress/breath shortness |
33(13.2%) |
8(13.1%) |
25(13.2%) |
0.587 |
Diarrhea |
15(7%) |
4(6.6%) |
11(5.8%) |
0.281 |
Nausea and vomiting |
10(4.0%) |
3(4.9%) |
7(3.7%) |
0.458 |
Severity assessment on admission, No. (%) |
|
|
|
|
Moderate |
192(76.8%) |
29(47.5%) |
163(86.2%) |
|
Serious |
46(18.4%) |
27(44.3%) |
19(10.1%) |
|
Critical |
12(4.8%) |
5(8.2%) |
7(3.7%) |
|
Treatment, No. (%) |
|
|
|
|
Arbidol |
145(60%) |
33(54.1%) |
112(59.2%) |
0.743 |
Lopinavir/Ritonavir |
66(26.4%) |
17(27.9%) |
49(25.9%) |
0.802 |
Interferon |
70(28.0%) |
20(32.8%) |
50(26.4%) |
0.616 |
Antibiotic |
135(54.0%) |
41(67.2%) |
94(49.7%) |
0.027 |
Traditional Chinese medicine |
209(83.6%) |
40(65.6%) |
169(89.4%) |
0.00 |
Glucocorticoid |
53(21.2%) |
23(37.7%) |
30(15.9%) |
0.00 |
Invasive mechanical ventilation |
13(5.2%) |
3(4.9%) |
10(5.3%) |
0.605 |
Anti-HBV/HCV treatment |
|
|
|
|
Entecavir |
6(2.4%) |
6(9.8%) |
0(0%) |
|
Abbreviation: COVID-19: Coronavirus Disease 2019; No.: Number; IQR: Interquartile Range.